netFormulary Central Lancashire Formulary NHS
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley and South Ribble CCG
Greater Preston CCG
 
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
06.01  Drugs used in diabetes
06.01.01  Insulins
06.01.01.01  Short-acting insulins
Insulin - Soluble Human
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Actrapid® 10ml vial; 

Humulin S® 10ml vial; 3ml cartridges

 
   
Insulin Aspart
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

NovoRapid® 10ml vial; FlexPen; 3ml penfill; PumpCart; FlexTouch

 
   
Insulin Aspart
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Fiasp® 10ml vial; FlexTouch pen; 3ml cartridge

 
   
Insulin Glulisine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Apidra® 10ml vial; Solostar pen

 
   
Insulin Lispro 100 units/ml
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Humalog® 10ml vial; Kwikpen; 3ml cartridges

 
   
Insulin 500 units in 1mL
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Humulin R Kwikpen®

 
   
06.01.01.02  Intermediate- and long-acting insulins
Insulin degludec (Tresiba®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Tresiba® pre-filled pen

Green (restricted) 

 
   
Insulin Detemir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Levemir® Flexpen; InnoLet; 3ml Penfill

 
   
Insulin Glargine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Abasaglar® Kwikpen; 3ml cartridges

Lantus® 10ml vial; 3ml cartridges; Solostar pen

 
   
Isophane Insulin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Humulin® I 10ml vial; Kwikpen; 

Isulatard® 10ml vial; Innolet; 3ml Penfill

 
   
Insulin Glargine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Toujeo® 300units per ml Solostar pen

             

 
   
06.01.01.02  Biphasic insulins to top
Biphasic Insulin Aspart
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

NovoMix® 30 Flexpen; 3ml Penfill

 
   
Biphasic Insulin Lispro
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Humalog® Mix 25 10ml vial; Kwikpen; 3ml cartrdige

Humalog® Mix 50 Kwikpen; 3ml cartridge

 
   
Biphasic Isophane Insulin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Humulin® M3 Kwikpen; 3ml cartridge

 
   
06.01.01.03  Hypodermic equipment
06.01.02  Antidiabetic drugs
06.01.02.01  Sulphonyureas
Gliclazide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Glimepiride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.01.02.02  Biguanides
Metformin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.01.02.03  Other antidiabetic drugs to top
06.01.02.03  Alpha glucosidase inhibitors
06.01.02.03  DPP4 inhibitors (gliptins)
Alogliptin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Linagliptin
(DPP4 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.01.02.03  GLP1 agonists
Dulaglutide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Trulicity®

Once Weekly Dose

 
   
Liraglutide
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Victoza®

Daily Dosing

 
Link  NICE TA203: Diabetes (type 2) - liraglutide
   
Semaglutide (Ozempic®)
(GLP1 agonist)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  NICE NG: Type 2 diabetes in adults: management
   
06.01.02.03  Meglitinides
06.01.02.03  SGL2 inhibitors to top
Empagliflozin
(SGLT-2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green
 
Canagliflozin
(SGLT2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug safety update: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
Link  NICE TA315: Canagliflozin for type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dapagliflozin
(SGLT-2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Blue

Treating type 2 diabetes:  Green

Combination therapy for treating type 2 diabetes : Green (restricted)

Triple therapy for treating type 2 diabetes: Green

 

Use with insulin for treating type 1 diabetes:   Amber

 
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Link  NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
   
Ertugliflozin (Steglatro®)
(SGLT-2 inhibitor)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Green (restricted)

 
Link  NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
   
06.01.02.03  Thiazolidinediones
Pioglitazone
(Thiazolidinedione)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug safety alert: Insulin combined with pioglitazone: risk of cardiac failure
Link  Drug safety alert: Pioglitazone: risk of bladder cancer
   
06.01.03  Diabetic ketoacidosis
06.01.04  Treatment of hypoglycaemia
Glucagon
View adult BNF View childrens BNF  Track Changes
Formulary
Green

GlucaGen® HypoKit

 
   
GlucoGel®
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.01.04  Chronic hypoglycaemia
06.01.05  Treatment of diabetic nephropathy and neuropathy to top
06.01.05  Diabetic nephropathy
06.01.05  Diabetic neuropathy
06.01.06  Diagnostic and monitoring agents for diabetes mellitus
06.01.06  Blood glucose monitoring
06.01.06  Urinalysis to top
06.01.06  Oral glucose tolerance test
Oral glucose tolerance test.
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

75g Anhydrous glucose

 
   
06.02  Thyroid and Antithyroid drugs
06.02.01  Thyroid hormones
Levothyroxine
(Thyroxine)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug safety update: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
   
06.02.02  Antithyroid drugs
Carbimazole
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Neo-Mercazole®

 
Link  Drug safety update: Carbimazole: increased risk of congenital malformations; strengthened advice on contraception
Link  Drug safety update: Carbimazole: risk of acute pancreatitis
   
Propylthiouracil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Iodine and Iodide
(Aqueous iodine oral solution)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
06.03  Corticosteroids to top
06.03.01  Replacement therapy
Fludrocortisone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
06.03.02  Glucocorticoid therapy
Betamethasone (Betnesol®)
(injection - systemic)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Dexamethasone
(tablets/injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Hydrocortisone
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Methylprednisolone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
Link  NICE CG186: Multiple Sclerosis; management in primary and secondary care.
   
Prednisolone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.03.02  Disadvantages of corticosteroids
06.03.02  Use of corticosteroids
06.03.02  Pregnancy and breastfeeding to top
06.03.02  Administration
06.03.02  Withdrawal of corticosteroids
06.04  Sex hormones
06.04.01  Female sex hormones and their modulators
06.04.01.01  Oestrogens and HRT to top
Combined continuous HRT patch
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Evorel® Conti

 
   
Combined continuous HRT tablet
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Kliofem® Kliovance® Femoston Conti® Premique® Elleste-Duet Conti®

 
   
Combined cyclical HRT patch
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Evorel Sequi®

 
   
Combined cyclical HRT tablet
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Elleste-Duet® Femoston® Prempak-C®

 
   
Oestrogen only HRT patch
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Evorel® Estradot® Elelste Solo® MX

 
   
Oestrogen only HRT tablet
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Elleste-Solo® Premarin®

 
   
Tibolone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Livial®

 
Link  Drug safety update: Tibolone, Increased risk of stroke in older women should be taken into account in prescribing decisions
   
06.04.01.01  Hormone replacement therapy
06.04.01.01  Ethinylestradiol
Ethinylestradiol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.04.01.01  Raloxifene
Raloxifene
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Blue

Primary prevention of osteoporotic fragility fractures in postmenopausal women: 

Black

Secondary prevention of osteoporotic fragility fractures in postmenopausal women: 

Green

 
Link  NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Link  NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
   
06.04.01.02  Progestogens
Medroxyprogesterone Acetate (Provera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Norethisterone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
06.04.02  Male sex hormones and antagonists to top
Testosterone and Esters (Sustanon 100®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Testosterone gel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber 1

Tostran ®

Testogel ®

BLACK (rag) rating for femaile sexual dysfunction following oophorectomy or ovarian failure. LMMG Review

 
   
Testosterone oral (Restandol Testocaps®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Testosterone undecanoate (Nebido®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
06.04.02  Anti-androgens
Cyproterone Acetate
(Male hypersexuality)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Dutasteride (Avodart®)
(Benign Prostatic Hyperplasia)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Finasteride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  Drug safety update: Finasteride: rare reports of depression and suicidal thoughts
Link  NICE CG97 Lower urinary tract symptoms: quick reference guide
   
06.04.03  Anabolic steroids
06.05  Hypothalamic and pituitary hormones and anti-oestrogens
06.05.01  Hypothalamic and anterior pituitary hormones and anti-oestrogens
06.05.01  Anti-oestrogens to top
Clomifene Citrate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
06.05.01  Anterior pituitary hormones
Somatropin (Saizen®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
BlueTeq
 
   
Tetracosactide (Synacthen®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
06.05.01  Hypothalmic hormones
Gonadorelin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

GnRH

 
   
Protirelin (TRH)
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Red
 
   
06.05.02  Posterior pituitary hormones and antagonists
06.05.02  Posterior pituitary hormones
Desmopressin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber 1
 
   
Terlipressin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Vasopressin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
06.05.02  Antidiuretic hormone antagonists to top
Demeclocycline
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Tolvaptan (Samsca®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq
 
Link  Drug safety update: Tolvaptan (Samsca): over-rapid increase in serum sodium risking serious neurological events
Link  Drug safety update: Tolvaptan (Samsca): risk of liver injury
Link  NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
   
06.06  Drugs affecting bone metabolism
06.06  Osteoporosis
06.06.01  Calcitonin and parathyroid hormone
Etelcalcetide (Parsabiv®)
(Treating secondary hyperparathyroidism)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
   
Teriparatide (Forsteo®)
(Secondary prevention of osteoporotic fragility fractures in postmenopausal women)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Recommendation is for women ONLY

(RAG Status is Black for men)

 
Link  NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
   
06.06.02  Bisphosphonates and other drugs affecting bone metabolism
06.06.02  Bisphosphonates to top
Alendronic Acid
(Once Daily)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Alendronic Acid
(Once-Weekly)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Ibandronic Acid
(osteoporosis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Ibandronic Acid injection (Bondronat)
(Bone metastases, Hypercalcaemia of malignancy)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Risedronate
(daily for Paget's)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Risedronate
(once weekly)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
   
Zoledronic Acid
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  Drug safety update: Intravenous zoledronic acid: adverse effects on renal function
   
06.06.02  Denosumab
Denosumab (XGEVA®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Blue

prevention of osteoporotic fractures in men and post menopausal women: 

Amber 1

treatment of Glucocorticoid-induced osteoporosis: Amber 1

 

Bone metastasis from solid tumours: Red

 

 
Link  Drug safety update: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal
Link  Drug safety update: Denosumab (Xgeva, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw-further measures to minimise risk
Link  NICE TA265: Bone metastases from solid tumours - denosumab: guidance
   
06.06.02  Strontium renelate
06.07  Other endocrine drugs
06.07.01  Bromocriptine and other dopaminergic drugs
Bromocriptine
(Hyperprolactinaemia)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Cabergoline
(Hyperprolactinaemia)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Quinagolide (Norprolac®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
06.07.02  Drugs affecting gonadotrophins to top
Danazol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
06.07.02  Gonadorelin analogues
Goserelin
(Non- malignant indications)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Leuprorelin
(Non- malignant indications)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Triptorelin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Decapeptyl® SR (Precocious Puberty)

 
   
Ulipristal (Esmya®)
(fibroids)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Black

Esyma®

See MHRA Safety Alert: Ulipristal

See LMMG Prescribing Guidance: Ulipristal

 
Link  LMMG Prescribing Guidance
   
06.07.02  Breast pain (mastalgia)
06.07.03  Metyrapone
Metyrapone (Metopirone®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
06.07.04  Somatomedins
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Little or no specific monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Brief prescribing document or information sheet may be required.  

Amber 1

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Minimal monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Full prior agreement about patient’s on-going care must be reached under the shared care agreement.  

Amber 2

Initiated by specialist and transferred to primary care following a successful initiation period. Significant monitoring required on an on-going basis. Full prior agreement about patient’s on-going care must be reached under the shared care agreement. Suitable for enhanced service.  

Black

NOT recommended for use by the NHS in Lancashire. Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.  

Blue

Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information  

Green

Appropriate for initiation and ongoing prescribing in both primary and secondary care. Generally, little or no routine drug monitoring is required.  

Purple

Low Priority for Prescribing - see Low Priority for Prescribing Policy  

Red

Medicine is supplied by the hospital for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.  

Red Specialist Centre

Prescribing restricted to Specialist Centres only  

netFormulary